New psychotropics: Amisulpride - Atypical compound in the group of 2nd generation antipsychotics;Nova psychofarmaka: Amisulprid - Atypicky preparat ve skupine antipsychotik 2. Generace

Psychiatrie

Volumn 4, Issue 3, 2000, Pages 191-200

  Svestka, J ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Amisulpride; Newer antipsychotics of the 2nd generation

Indexed keywords

AMISULPRIDE; NEUROLEPTIC AGENT;

DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; HUMAN; REVIEW; SCHIZOPHRENIA;

EID: 0033693803     PISSN: 12117579     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Do novel antipsychotics have similar pharmacological characteristics?
2. Evidence for a functional role of the dopamine D3 receptors in the cerebellum
3. Treatment of negative symptoms in schizophrenia with amisulpride
4. Amisulpride in the treatment of acute schizophrenia: A doubleblind comparison with haloperidol
5. Amisulpride versus amineptine and placebo for the treatment of dysthymia
6. Amisulpride - Long-term safety
7. Quality of life: Superiority of amisulpride versus haloperidol, a 12-month study
8. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group
9. Amisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia
10. Safety of amisulpride (Solian). A pooled review of 11 clinical studies
11. Effects of amisulpride, an atypical antipsychotic which blocks preferentially presynaptic dopamine autoreceptors, on integrated functional cerebral activity in the rat
12. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride
13. Amisulpride versus haloperidol in treatment of schizophrenic patients - Results of a double-blind study
14. Potentiation of prepulse inhibition of the startle reflex in rats: Pharmacological evaluation of the procedure as a model for detecting-antipsychotic activity
15. Effects of acute and repeated administration of amisulpride, a dopamine D2/D3 receptor antagonist, on the electrical activity of midbrain dopaminergic neurons
16. Pharmacokinetic and metabolism of amisulpride
17. The safety profile of amisulpride, an atypical antipsychotic
18. Social adaptation in schizophrenic patients: Experience with amisulpride
19. Neuroendocrine response to antipsychotics: Effect of drug type and gender
20. Safety and pharmacokinetic of single oral dose of amisulpride in healthy volunteers
21. Onset of action in the pharmacologic treatment of dysthymia
22. Amisulpride. From pharmacological profile to clinical outcome
23. Amisulprid - Ein atypisches antipsychotikum in der behandlung schizophrener erkrankungen
24. Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group
25. Suicidal behaviour in amisulpride treated patients: A pooled review of 11 clinical studies
26. Olanzapine versus amisulpride and placebo in the treatment of negative symptoms and deficit states of chronic schizophrenia
27. The acute effects of amisulpride (50 mg and 260 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers
28. Efficacy and safety of amisulpride versus haloperidol: A 4-month assessment
29. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
30. Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics
31. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia
32. Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects
33. Improvement of acute exacerbations of schizophrenia with amisulpride: A comparison with haloperdiol
34. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
35. Antidepressant-like activity of amisulpride in two animal models of depression
36. Effects of 50 mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep-deprived subjects
37. Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers
38. Psychopharmacological profile of amisulpride. An antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity
39. Amisulpride v. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride Study group
40. Etude multicentrique controlee en double insu. Amisulpride (Solian 200) versus haloperidol a forte dose dans les etats psychotiques aigues
41. A double-blind, controlled, multicenter trial of low dose amisulpride (Solian 50) versus low dose fluphenazine in the treatment of negative symptoms in chronic schizophrenia
42. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs. haloperidol
43. Amisulpride in medium-term treatment of dysthymia: A six-month, double-blind safety study versus amitriptyline, AMILONG investigators
44. Clinical update on amisulpride in deficit schizophrenia
45. Amisulpride improves affective symptoms in acute schizophrenia
46. Treatment-emergent tardive dyskinesia in the long-term treatment of schizophrenia: A comparison of amisulpride and haloperidol
47. Clinical, EEG mapping and psychometric studies in negative schizophrenia: Comparative trial with amisulpride and fluphenazine
48. Amisulpride: From animal pharmacology to therapeutic action
49. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity
50. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: A double-blind, comparative study
51. Localization and function of the D3 dopamine receptor
52. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistant negative symptoms. Amisulpride v. haloperidol
53. Nova antipsychotika II. Generace: Olanzapin
54. Nova psychofarmaka: Sertindol
55. Nova psychofarmaka: Antipsychotikum quetiapin
56. Atypical antipsychotics and weight gain - A systematic review
57. Amisulpride poisoning: A report on two cases
58. Onset of action in acute schizophrenia, amisulpride versus haloperidol
59. Acute antagonism of dopamine D2-like receptors by amisulpride: Effects on hormone secretion in healthy volunteers
60. Amisulpride versus flupentixol in schizophrenia with predominant positive symptomatology - A double-blind controlled study comparing a selective D2-like antagonist, to a mixed D1-/D2-like antagonist
61. Amisulpride, neuroleptic and antinegative action